<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1531">
  <stage>Registered</stage>
  <submitdate>22/08/2006</submitdate>
  <approvaldate>28/08/2006</approvaldate>
  <actrnumber>ACTRN12606000374561</actrnumber>
  <trial_identification>
    <studytitle>VYTUL</studytitle>
    <scientifictitle>A multi-centre, randomised, open-label parallel groups study comparing the effectiveness and safety of treatment with Vytorin (Ezetimibe and Simvastatin) versus Lipitor (Atorvastatin) in subjects with a history of coronary heart disease and/or diabetes mellitus with uncontrolled lipids on statin therapy.</scientifictitle>
    <utrn />
    <trialacronym>VYTUL</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Hypercholesterolaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The duration of the study will be approximately 8 weeks involving 4 visits. Randomisation to treatment groups: Vytorin 10/40 (Ezetimibe 10mg /Simvastatin 40mg) ; both these medications are registered in Australia.</interventions>
    <comparator>Lipitor  (Atorvastatin 80 mg) daily orally for six weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily in reducing the concentration of Low density lipoprotein cholesterol (LDL-C) at endpoint</outcome>
      <timepoint>After 6 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. the percentage of participants who achieve the target LDL-C concentration of &lt; 2.0 mmol/L.</outcome>
      <timepoint>To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily after 6 weeks of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. change in the concentrations of each of the following parameters: total cholesterol, High density lipoprotein cholesterol (HDL-C), LDL-C/HDL ratio, Triglycerides (TG), apolipoprotein B (apoB) and non-HDL cholesterol.</outcome>
      <timepoint>To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily after 6 weeks of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. safety and tolerability with respect to Creatine Kinase (CK), Aspartate aminotransferase (AST), Alanine amino transferase (ALT) concentrations and incidence of both Non Serious Adverse and Serious Adverse Events.</outcome>
      <timepoint>To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily after 6 weeks of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Capable of and willing to sign written informed consent- Has been treated for at least the last 3 months with a daily dose of atorvastatin40 mg- Existing coronary heart disease and has cholesterol &gt; 4.0 mmol/L measured at Visit 1 OR diabetes mellitus and has measured at Visit 1 cholesterol &gt; 6.5 mmol/L OR cholesterol &gt; 5.5 mmol/L and HDL &lt; 1 mmol/L- Free of any clinically significant diseases, other than hyperlipidaemia, that would interfere with study evaluations and willing and able to attend all study visits.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Uncontrolled diabetes, defined by a measured HbA1c &gt; 9% as measured at Visit 1-Has alanine aminotransferase (ALT) &gt; 1.5 times Upper Limit of Normal (ULN) as measured at Visit 1- Has aspartate aminotransferase (AST) &gt; 1.5 times ULN as measured at Visit 1-Has creatine kinase (CK) &gt; 1.5 times ULN as measured at Visit 1- Has triglycerides (TG) &gt; 4.5 mmol/L as measured at Visit 1- Has evidence of renal impairment with a serum creatinine &gt; 200 Âµmol/L as measured at Visit 1- Has known drug or alcohol dependency within 6 months prior to Visit 1-A woman receiving hormonal therapy, including hormone replacement, anyestrogen antagonist/agonist, or oral contraceptives, who have not beenmaintained on a stable dose and regimen for at least 8 weeks and are willingto continue the same regimen for the duration of the study.- A woman of childbearing potential (includes women who are less than 1 yearpostmenopausal or not surgically sterile) not using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condomin combination with spermicide)- Women who are pregnant or breast feeding- Any condition or situation which, in the opinion of the investigator, might pose arisk to the subject or interfere with participation in the studyProhibited Medication for the Duration of the Study- Medications taken within 5 weeks prior to Visit 1 (Screening Visit) including: macrolide antibiotics, azole antifungals, fibric acid derivatives, niacin- Other medication as listed in the product information sheets for ezetimibe/simvastatin and atorvastatin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone/fax/computer</concealment>
    <sequence>Permuted Block 1:1 randomisation stratified by site, block size not disclosed to investigators</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>550</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck Sharp &amp; Dohme Australia &amp; Schering-Plough Pty. Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Sharp &amp; Dohme Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering-Plough Pty. Limited</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Monash University Dept of Epidemiology &amp; Preventive Medicine,</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>CCRE in Therapeutics</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine if the introduction of Vytorin will be more effective than increasing the dose of Atorvastain in achieving LDL ('bad cholesterol') and other cholesterol level goals in high risk patients who have been treated for at least the last three months with atorvastatin 40 mg and still have uncontrolled cholesterol levels.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash University Department of Epidemiology &amp; Preventive Medicine CCRE in Therapeutics</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Clinical Trials Centre Caulfield General Medical Centre-Alfred Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>31/07/2006</ethicapprovaldate>
      <hrec>162/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Chris Reid - Co Principal Investigator</name>
      <address>Monash University Clinical Trials Centre 
Ground Floor Fethers Block
Department of Epidemiology and Preventive Medicine - CCRE in Therapeutics
Monash University
Level 3 Burnet Bldg
89 Commercial Road
MELBOURNE VIC 3004</address>
      <phone>+61 3 9903 0752</phone>
      <fax />
      <email>chris.reid@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Louise Shiel - Project Manager</name>
      <address>Monash University Clinical Trials Centre 
Ground Floor Fethers Block
Caulfield General Medical Centre
260 Kooyong Road
CAULFIELD VIC 3162</address>
      <phone>+61 3 9276 6166</phone>
      <fax>+61 3 9276 6249</fax>
      <email>louise.shiel@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>